Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Luo, Hui; Lü, Jin; Bai, Yuxian; Mao, Teng; Wang, Jun; Fan, Qingxia; Zhang, Yiping; Zhao, Kuaile; Chen, Zhendong; Gao, Shegan; Li, Jiancheng; Fu, Zhichao; Gu, Kangsheng; Liu, Zhihua; Wu, Lin; Zhang, Xiaodong; Feng, Ji‐Feng; Niu, Zuoxing; Ba, Yi; Zhang, Helong; Liu, Ying; Zhang, Li; Min, Xuhong; Huang, Jing; Cheng, Ying; Wang, Dong; Shen, Yu; Yang, Qing; Zou, Jianjun; Xu, Rui‐Hua; Investigators, ESCORT-1st; Yuan, Xianglin; Ma, Dong; Liu, Emily; Ye, Feng; Liu, Tianshu; Wang, Xiuwen; Liu, Likun; Xia, Bing; Ran, Fengming; Sun, Sanyuan; Miao, Zhanhui; Bie, Jun; Gao, Yong; Yu, Junyan; Chen, Li; He, Yifu; Ren, Wei; Luo, Suxia; Zhao, Guangqiang; Lin, Youen; Chen, Long; Guo, Zhiyuan; Hu, Chunhong; Wang, Ying; Xu, Nong; Chen, Baofu; Zhan, Xianbao; Chen, Yuping; Lu, Hongda; Qin, Shukui; Wang, Guolei; Chen, Liming; Bai, Li; Zhang, Jingdong

doi:10.1001/jama.2021.12836

Public

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Published in JAMA • Sep 14, 2021

Authors:

Hui Luo

Jin Lü

Yuxian Bai

Abstract

Importance: Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced or metastatic esophageal squamous cell ...

Subject

Medicine

Internal medicine

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!